Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice.

Akada H, Akada S, Hutchison RE, Mohi G.

Leukemia. 2014 Aug;28(8):1627-35. doi: 10.1038/leu.2014.52. Epub 2014 Jan 31.

2.

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, Vainchenker W, Villeval JL.

Blood. 2010 Aug 5;116(5):783-7. doi: 10.1182/blood-2009-12-257063. Epub 2010 May 14.

3.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

4.

Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.

Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V.

Exp Hematol. 2009 Oct;37(10):1194-200. doi: 10.1016/j.exphem.2009.07.003. Epub 2009 Jul 15.

PMID:
19615425
5.

Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.

Yan D, Jobe F, Hutchison RE, Mohi G.

Leukemia. 2015 Oct;29(10):2050-61. doi: 10.1038/leu.2015.116. Epub 2015 May 18.

6.

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG.

Blood. 2010 Apr 29;115(17):3589-97. doi: 10.1182/blood-2009-04-215848. Epub 2010 Mar 2.

7.

Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.

Martínez-Trillos A, Maffioli M, Colomer D, Alvarez-Larrán A, Pereira A, Angona A, Bellosillo B, Cervantes F.

Ann Hematol. 2014 May;93(5):797-802. doi: 10.1007/s00277-013-1989-5. Epub 2013 Dec 15.

PMID:
24337516
8.

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.

Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP.

Eur J Haematol. 2010 Jun;84(6):518-24. doi: 10.1111/j.1600-0609.2010.01428.x. Epub 2010 Mar 11.

PMID:
20331734
9.

Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.

Li L, Bailey E, Greenblatt S, Huso D, Small D.

Blood. 2011 Nov 3;118(18):4935-45. doi: 10.1182/blood-2011-01-328096. Epub 2011 Sep 8.

10.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
11.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
12.

JAK2V617F allele burden in patients with myeloproliferative neoplasms.

Alshemmari SH, Rajaan R, Ameen R, Al-Drees MA, Almosailleakh MR.

Ann Hematol. 2014 May;93(5):791-6. doi: 10.1007/s00277-013-1988-6. Epub 2013 Dec 22.

PMID:
24362471
13.

Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Lamrani L, Lacout C, Ollivier V, Denis CV, Gardiner E, Ho Tin Noe B, Vainchenker W, Villeval JL, Jandrot-Perrus M.

Blood. 2014 Aug 14;124(7):1136-45. doi: 10.1182/blood-2013-10-530832. Epub 2014 Jun 20.

14.

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, Villeval JL.

Blood. 2013 Aug 22;122(8):1464-77. doi: 10.1182/blood-2013-04-498956. Epub 2013 Jul 17.

15.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
16.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
17.

Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.

Koh SP, Yip SP, Lee KK, Chan CC, Lau SM, Kho CS, Lau CK, Lin SY, Lau YM, Wong LG, Au KL, Wong KF, Chu RW, Yu PH, Chow EY, Leung KF, Tsoi WC, Yung BY.

BMC Genet. 2014 Dec 20;15:147. doi: 10.1186/s12863-014-0147-y.

18.

Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.

Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, Najfeld V, Zhao ZJ, Hoffman R, Wisch N, Xu M.

Leukemia. 2009 Sep;23(9):1577-86. doi: 10.1038/leu.2009.85. Epub 2009 Apr 23.

PMID:
19387466
20.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026

Supplemental Content

Support Center